Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT03446261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03446261
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03446261. Randomized; no masking; primary purpose treatment. Start 2018-02-23 (actual); primary completion 2019-03-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia
Condition
Type 2 Diabetes Mellitus
Condition
Hypercholesterolemia
Intervention (Drug)
Rosuvamibe® Tab
Intervention (Drug)
Monorova® Tab
Lead sponsor
Yuhan Corporation (class: industry)

Record details

Record id
cardio:ct-nct03446261
Content hash
1aeed12610238e87b43d270143cecef32c5a7459536a6e7eae10b285ec23a059